Eli Lilly and Co (LLY)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$1,061.31

Buy

$1,062.46

arrow-down$-0.3025 (-0.03%)

Prices updated at 16 Dec 2025, 15:10 EST

Prices minimum 15 mins delay

Prices in USD

Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

S&P 500

-0.2%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2023	2024
	34,124m	45,043m
	27,042m	36,624m
	10,787m	17,502m
	31.61	38.86
	5,240m	10,590m
	8,568m	15,228m
Sales, General and administrative	6,941m	8,132m
Interest expenses	486m	781m
Provision for income taxes	1,314m	2,090m
Operating expenses	16,255m	19,123m
Income before taxes	6,555m	12,680m
Net income available to common shareholders	5,240m	10,590m
	5.82	11.76
Net interest income	-312m	-605m
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	5.8	11.71
Free cash flow per share	-0.1825	-2.5162
Book value/share	12.4757	15.8656
Debt equity ratio	1.700796	2.010069

Balance sheet

Year chevron-l-regular chevron-r-regular	2023	2024
Current assets	25,727m	32,740m
Current liabilities	27,293m	28,377m
Total capital	29,093m	42,719m
Total debt	25,225m	33,644m
Total equity	10,772m	14,192m
Total non current liabilities	-	-
Loans	18,321m	28,527m
Total assets	64,006m	78,715m
Total liabilities	-	-
Cash and cash equivalents	2,819m	3,268m
Common stock	899m	898m

Cash flow

Year chevron-l-regular chevron-r-regular	2023	2024
Cash at beginning of period	2,067m	2,819m
Cash dividends paid	-4,069m	-4,680m
	-3,152m	414m
Investments (gains) losses	-7,153m	-9,301m
	2,819m	3,268m
Net income	-	-
	4,240m	8,818m
	-7,392m	-8,404m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.